Date:5/1/2012

ciles the specific items excluded from GAAP other income and expense in the calculation of non-GAAP other income and expense for the periods shown below:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Other Income and Expense(Unaudited)(in thousands)Three Months Ended March 31, 2012April 2, 2011Other income (expense) on a GAAP basis $ 731$ (2,125)Impact of ASC 470-20-1,883Other income (expense) on a non-GAAP basis $ 731$ (242)The following table reconciles the GAAP tax expense adjusted for the tax effect of the adjustments from GAAP net income to non-GAAP net income:THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP Tax Expense(Unaudited)(in thousands)Three Months Ended March 31, 2012April 2, 2011Tax expense on a GAAP basis

$ (12,230)

32.4%

$ (8,501)

34.1%Share-based compensation expense

(2,008)(1,704)Amortization of purchased intangibles

(1,012)(921)Impact of adoption of ASC 470-20

-(753)Excess compensation limitations and other

267605Levitronix fair market value inventory adjustments

(142)-Tax expense on a non-GAAP basis

$ (15,125)

33.1%

$ (11,274)

34.1% 

The following table reconciles the guidance on a GAAP basis and non-GAAP basis for the periods shown below: THORATEC CORPORATIONReconciliation of GAAP to Non-GAAP  Forward-Looking Guidance(Unaudited)(in thousands, except for per share data)Gross margin For the Fiscal Year Ended 2012 FromToGross margin on a GAAP basis

68.50%69.00%Amortization of purchased intangibles

1.80%1.80%Levitronix fair market value inventory adjustments

0.40%0.40%Share-based compensation expense

0.30%0.30%Gross margin on a non-GAAP basis

71.00%71.50%Net income per diluted share reconciliation For the Fiscal Year Ended 2012 FromToNet income per diluted share on a GAAP basis

$  1.24$  1.34Share-based compensation e
'/>"/>

SOURCE Thoratec Corporation Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related medicine technology :

1. Thoratec Schedules First Quarter Conference Call, Webcast
2. Thoratec Comments on February 23rd Voluntary Medical Device Correction Notification
3. Thoratec Presentation at Leerink Swann Healthcare Conference to be Webcast
4. Thoratec Schedules Fourth Quarter Conference Call, Webcast
5. Thoratec Announces Appointment of William A. Hawkins to Board of Directors
6. Thoratec Presentation at Oppenheimer Conference to Be Webcast
7. Thoratec Corporation Authorizes Additional $50 Million Share Repurchase Program
8. Thoratec Reports Third Quarter Fiscal 2011 Results
9. Thoratec Schedules Third Quarter Conference Call, Webcast
10. Thoratec Presentation at Lazard Capital Markets Circulatory Assist Device Day to be Webcast
11. Thoratec Announces Presentations at Upcoming Investor Conferences